Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2022 Operational and Financial Results on November 2, 2022
October 27 2022 - 07:00AM
GlobeNewswire Inc.
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a
clinical-stage biopharmaceutical company focused on improving the
intracellular delivery of nucleic acids and small molecules with
its lipid nanocrystal (LNC) platform delivery technology, today
announced the company will host a conference call and live audio
webcast on Wednesday, November 2, 2022 at 4:30 p.m. ET to discuss
operational and financial results for the third quarter ended
September 31, 2022.
To participate in the call, please dial
888-609-1607 (Toll-Free) or (862) 298-0702 (Toll). The live webcast
will be accessible on the Investors section of Matinas’ website,
www.matinasbiopharma.com, and archived for 90 days.
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company
focused on improving the intracellular delivery of nucleic acids
and small molecules with its lipid nanocrystal (LNC) platform
technology. The Company is developing its own internal portfolio of
products as well as partnering with leading pharmaceutical
companies to develop novel formulations that capitalize on the
unique characteristics of the LNC platform.
Preclinical and clinical data have demonstrated
that this novel technology can provide solutions to many of the
challenges in achieving safe and effective intracellular delivery,
for both small molecules and larger, more complex molecules, such
as mRNA, DNA plasmids, antisense oligonucleotides, and vaccines.
The combination of a unique mechanism of action and flexibility
with formulation and route of administration (including oral),
positions Matinas’ LNC technology to potentially become the
preferred next-generation intracellular drug delivery vehicle with
distinct advantages over both lipid nanoparticles and viral
vectors.
Forward Looking Statements
This release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including those relating to our business
activities, our strategy and plans, our collaboration with
BioNTech, the potential of our LNC platform delivery technology,
and the future development of its product candidates, including
MAT2203, MAT2501, the anticipated timing of regulatory submissions,
the anticipated timing of clinical studies, the anticipated timing
of regulatory interactions, the Company’s ability to identify and
pursue development and partnership opportunities for its products
or platform delivery technology on favorable terms, if at all, and
the ability to obtain required regulatory approval and other
statements that are predictive in nature, that depend upon or refer
to future events or conditions. All statements other than
statements of historical fact are statements that could be
forward-looking statements. Forward-looking statements include
words such as "expects," "anticipates," "intends," "plans,"
"could," "believes," "estimates" and similar expressions. These
statements involve known and unknown risks, uncertainties and other
factors which may cause actual results to be materially different
from any future results expressed or implied by the forward-looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, our ability
to obtain additional capital to meet our liquidity needs on
acceptable terms, or at all, including the additional capital which
will be necessary to complete the clinical trials of our product
candidates; our ability to successfully complete research and
further development and commercialization of our product
candidates; the uncertainties inherent in clinical testing; the
timing, cost and uncertainty of obtaining regulatory approvals; our
ability to protect the Company’s intellectual property; the loss of
any executive officers or key personnel or consultants;
competition; changes in the regulatory landscape or the imposition
of regulations that affect the Company’s products; and the other
factors listed under "Risk Factors" in our filings with the SEC,
including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to
place undue reliance on such forward-looking statements, which
speak only as of the date of this release. Except as may be
required by law, the Company does not undertake any obligation to
release publicly any revisions to such forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. Matinas BioPharma’s
product candidates are all in a development stage and are not
available for sale or use.Investor and Media
Contacts
Ankit Bhargava, MDAllele
Communications815.721.4912matinas@allelecomms.com
Source: Matinas BioPharma Holdings, Inc.
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From May 2023 to Jun 2023
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Jun 2022 to Jun 2023